Penny A. Asbell, MD

ARMOR surveillance study update gives current insights on antibiotic resistance for clinical ocular isolatesThe most recent analyses of data from the ARMOR (Antibiotic Resistance Monitoring in Ocular micRoorganisms) Surveillance Program can guide clinicians choosing antibiotic therapy for initial empiric therapy and infection prophylaxis. The information also reinforces the importance of prudent antibiotic prescribing to limit the development of bacterial resistance to existing options, according to Penny Asbell, MD.
Webinar: The ARMOR study five-year surveillance resultsWatch as Penny Asbell, MD, talks about antibiotic resistance in a webinar titled: The ARMOR Study Five-Year Surveillance Results.
What ARMOR update means for ocular infectionsTailor antibiotic choices for each patient, as resistance remains high, according to the 2015 Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) update.
Clinical advice from the latest ARMOR study updateIn the most recent update from the ARMOR study, Penny Asbell, MD, FACS, MBA, explained that clinicians must choose their antibiotics carefully.
Antibiotic resistance levels shift among ocular pathogens in 2014 ARMOR dataNew surveillance data on antibiotic resistance among ocular pathogens shows worrisome trends for some widely used drugs while resistance rates for some isolates were relatively stable.